Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CING vs INSM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INSM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

INSM Overall Winner 6-Pillar Tally: CING 2 – 3 INSM (1 Tie) Matrix Metrics: CING 3 – 6 INSM

As of Nov 17, 2026, Insmed, Inc. (INSM) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas INSM carries 34.3/100 (SELL) at $121.44 (N/M Forward P/E, -41.7% operating margin).

  • Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. INSM 34.3/100 SELL), INSM captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-41.7% vs. 0.0% operating margin) and revenue trajectory (+268.4% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.9); meanwhile INSM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 63.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CING vs INSM
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.13β · 117% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $4.71 · SMA50: $4.82
INSM NASDAQ Head-to-Head Winner
Insmed, Inc.
Pharmaceutical Preparations
$121.44
-1.18% 1D
Market Cap $26.6B
TTM Revenue $1.52B
Forward P/E N/M
Beta / 30D Vol 0.65β · 62% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 33.0 Flow 68.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 64
RSI-14: 63.7 · SMA20: $108.94 · SMA50: $110.68

6-Pillar Scorecard Institutional Category Breakdown (CING 2 – 3 INSM)

Columns: Metric · CING · INSM
1. Valuation Multiples INSM
Forward P/E N/M N/M
Trailing P/E N/M 107.5x
PEG Ratio N/M 1.09x
EV / Revenue N/M 17.6x
2. Growth & Scale INSM
Revenue Growth (YoY) +0.0% +268.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.52B
Market Cap $62.5M $26.6B
3. Profitability & Quality CING
Gross Margin N/A 84.4%
Operating Margin 0.0% -41.7%
Net Profit Margin 0.0% -39.9%
Return on Equity (ROE) -198.7% -72.5%
4. Balance Sheet & Cash Flow CING
Cash Generation (TTM) -$21M -$628M
Cash Flow Margin N/A -41.3%
Net Cash / Leverage $22M Net Cash $188M Net Debt (0.81x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INSM
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 111.1% (16th %ile) 52.3% (38th %ile)
Put/Call OI Skew 0.07x (Call-Skewed) 0.03x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CING (3) vs INSM (6)
Institutional Metric CING INSM Criterion Row Edge
Market Capitalization
Scale
$62.5M $26.6B Larger Scale INSM
Trailing P/E Ratio
Valuation
N/M 107.5x Lower Multiple INSM
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +268.4% Higher Growth INSM
Operating Margin (TTM)
Profitability
0.0% -41.7% Higher Margin CING
Net Profit Margin
Profitability
0.0% -39.9% Higher Margin CING
Return on Equity (ROE)
Capital Efficiency
-198.7% -72.5% Higher ROE INSM
52-Week Range Position
Momentum
18% ($3–$12) 25% ($90–$213) Stronger Trend INSM
Beta / 30D Volatility
Risk Regime
1.13β · 117% Vol 0.65β · 62% Vol Lower Realized Risk INSM
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite CING
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 84.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.09x PEG · 17.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($22M Net Cash) -$628M ($188M Net Debt (0.81x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INSM +18.27 pp
CING: +9.17% · INSM: +27.44%
3M Horizon INSM +2.62 pp
CING: -9.68% · INSM: -7.06%
6M Horizon INSM +4.63 pp
CING: +8.43% · INSM: +13.06%
1Y Horizon CING +73.54 pp
CING: +36.39% · INSM: -37.15%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs INSM. Trailing 12-month operating profitability (CING 0.0% vs INSM -41.7%) and valuation multiples (CING N/M vs INSM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M
INSM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.52B
Gross Margin84.4%
Op. Margin-41.7%
ROE / Fwd P/E-72.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INSM CONSOLIDATION
70d in phase · OBV ACCUMULATION
Current IV 52.3%
IV Percentile 38th %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact INSM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $122.88 · IV 50.1%

INSM Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($12,288)

Compare $12,288 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 50.1% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $125 / $135 Bull Call Spread

Buy 1x $125C · Sell 1x $135C · 32d

Net Entry $360 Debit
T+5d @ +5% Move +$119 (+33%)
Max Risk / Buffer $360 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $110 / $100 Bull Put Spread

Sell 1x $110P · Buy 1x $100P · 60d

Net Entry $215 Credit
Max Credit / Yield +$215 (+27.4% RoM)
Max Risk / Buffer -12.2% Cushion ($785 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $115P / $125-$140C Seagull

Sell 1x $115P · Buy 1x $125/$140C · 32d

Net Entry $150 Debit
T+5d @ +5% Move +$356 (+16.6% RoM)
Max Risk / Buffer -6.4% Put Cushion ($2,150 Mgn)
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INSM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $26.6B market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CING vs INSM Key Questions & Quantitative Answers

As of Nov 17, 2026, Insmed, Inc. (INSM) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas INSM carries 34.3/100 (SELL) at $121.44 (N/M Forward P/E, -41.7% operating margin). Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. INSM 34.3/100 SELL), INSM captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-41.7% vs. 0.0% operating margin) and revenue trajectory (+268.4% vs. +0.0% YoY). Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.9); meanwhile INSM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 63.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INSM leads the Growth & Scale pillar: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with INSM at +268.4% YoY revenue growth and +0.0% YoY earnings growth on $1.52B TTM revenue (84.4% gross margin, -41.7% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus $1.52B for INSM. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INSM.

INSM screens cheaper on headline valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas INSM trades at N/M Forward P/E, 107.5x Trailing P/E, 1.09x PEG, and 17.6x EV/Revenue (-41.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus INSM (-72.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, INSM carries 52.3% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.65β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.